Mo1180 Sustained Leukopenia Not Observed in Patients With Thiopurine-Associated Lymphoma and Ulcerative Colitis

Abstract

INTRODUCTION: The general increased life expectancy is reflected in the age of patients with inflammatory bowel disease (IBD). The knowledge about efficacy and safety of antitumor necrosis factor (TNF) therapy in elderly is scarce and conflicting. Our objectives were to assess the efficacy and safety of anti-TNF therapy in elderly patients taking into account eventual comorbidity. METHODS: In this retrospective single-centre study we compared 63 IBD patients initiating anti-TNF treatment at age ≥ 65 years (cases) to 118 IBD patients initiating anti-TNF at age 0 were risk factors for malignancy and mortality. CONCLUSION: Elderly patients treated with anti-TNF have a lower rate of clinical response (regardless of their comorbidity). The rate of adverse events is higher in elderly patients but especially in those with a higher comorbidity.